首页 > 市场调查报告书 > 医疗设备

眼科设备

市场调查报告书

商品编码

1439710

眼科植入物 - 全球市场回顾、竞争格局、市场预测 (2030)

Ocular Implants - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 按订单生产 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

简介目录图表

预计2023年全球眼部植入物市场规模将达到50.6043亿美元，到2030年将达到65.6146亿美元，2024-2030年预测期间复合年增长率为4.51%。由于青光眼、白内障、老花眼和近视等各种眼部疾病病例的增加，全球老年人口负担的增加，以及技术进步进一步提高产品安全性和生物相容性等因素，该市场预计将增长。预计在预测期内（2024-2030）营收将显着成长。

眼植入物市场动态

眼部植入物市场的显着驱动因素之一是白内障、青光眼、老花眼和近视等眼部疾病的盛行率不断上升。例如，根据世界卫生组织（WHO）（2023）的数据，全球近视或远视的人数已达到惊人的22亿，其中近一半的人无法预防视力障碍。，但尚未解决。根据同一数据，2020年未经治疗的白内障和青光眼患者人数分别为9,400万人和770万人。此外，近视和老花眼等屈光不正预计未来还会增加。例如，根据国际近视研究所（2023）的数据，目前全球有30%的人近视，到2050年，近视人口将增加至50%，达到50亿人。上述文件进一步指出，近视在东亚和东南亚地区较为常见，在韩国、中国和日本等国家，近视盛行率高达80%至90%。就老花眼而言，根据世界卫生组织（WHO）在其《世界视力报告（2019）》中引用的数据，2018年全球约有18亿老花眼病例。

此外，老年人口的增加，容易罹患多种眼部疾病，包括白内障、老年黄斑部病变（AMD）、青光眼、糖尿病视网膜病变、老花眼等，预计将进一步加速眼部植入物市场的发展。根据世界卫生组织（2023）提供的数据，2020年，全球约有10亿人年龄在60岁或以上。上述数据预测，到2050年，60岁以上老年人口将翻一番，达到约21亿人。此外，预计 2020 年至 2050 年间，80 岁及以上的人口将增加两倍，达到 4.26 亿人。

然而，缺乏优质晶状体覆盖以及与手术程序和设备相关的併发症可能是眼部植入物市场的限制因素。

由于实施封锁作为打破 COVID-19 感染链的必要措施，眼部植入物市场的市场成长出现了短期挫折。 COVID-19 大流行导致医疗服务和程序发生重大重组。许多国家根据紧急医疗需求将医疗程序分开，并暂停了各种被认为是选择性的医疗程序，以在 COVID-19 危机期间简化工作流程。例如，2020年3月，美国眼科学会（AAO）建议眼科医生取消所有常规门诊，并将其服务仅限于急诊患者。 AAO 也建议临床活动可以在遵守当地法规的情况下谨慎继续。此外，在封锁期间，眼部植入物的购买变得困难，眼内手术的数量也减少了。因此，产品需求低于正常水准。然而，包括医疗产业在内的各行业活动的恢復正在推动眼部植入物市场的发展，预计将在 2024 年至 2030 年的预测期内推动成长。

眼科植入物细分市场分析

在眼部植入物市场的类型细分市场中，人工水晶体类别占2022年收入占有率最高，达78%。

这是由于人工水晶体的不同特性、技术优势以及合作研究和监管审批等产品开发活动的增加。

本报告提供了全球眼植入物市场的研究和分析，包括市场规模和预测、驱动因素和挑战以及公司和产品概况。

眼植入物市场驱动因素
- 白内障、青光眼、老花眼、近视等眼部疾病增加
- 全球人口老化负担日益加重
- 产品设计的技术进步
眼科植入物市场的限制与挑战
- 与手术和装置相关的併发症
- 缺乏优质镜片覆盖范围
眼部植入物市场机遇
- 提高产品安全性与生物相容性
- 先进眼部植入物的开发取得进展

第5章眼植入物市场波特五力分析

第6章COVID-19对眼科植入物市场的影响分析

第7章眼科植入市场布局

依类型
- 人工水晶体
- 角膜植入物
- 青光眼植入物
- 人工虹膜
- 其他
依材质
- 可生物降解
- 不可生物降解
依用途
- 白内障
- 青光眼手术
- 眼部整形
- 药物输送
- 黄斑部病变
按最终用户
- 医院
- 眼科诊所
- 门诊手术中心
按地区
- 北美
- 欧洲
- 亚太地区
- 其他领域

第8章眼部植入物市场公司及产品概况

Alcon
Johnson & Johnson Services Inc.
Bausch Health Companies Inc.
ZEISS International
Glaukos Corporation
AbbVie Inc.
MORCHER® GmbH
HumanOptics Holding AG
Alimera Sciences
Advanced Artificial Eyes
Erickson Laboratories
Midwest Eye Laboratories, Inc.
EyeYon
EyePoint Pharmaceuticals, Inc.
HOYA Corporation
SMR Ophthalmic Pvt. Ltd.
Gulden Ophthalmics
AJL Ophthalmic S.A.
KeraMed, Inc.
Innovia Medical

第9章KOL浏览量

第 10 章专案方法

第 11 章关于 DelveInsight

第 12 章免责声明与联络我们

简介目录图表

Product Code: DIMDCL0554

Ocular Implants Market By Type (Intraocular Lenses, Corneal Implants, Glaucoma Implants, Artificial Iris, And Others) By Material (Biodegradable And Non-Biodegradable), By Application (Cataract, Glaucoma Surgery, Oculoplasty, Drug Delivery, Macular Degeneration, And Others), By End-User (Hospitals, Eye Speciality Clinics, And Ambulatory Surgical Centres) and by geography is estimated to register a growth at a remarkable CAGR forecast during 2024-2030 owing to surge in the cases of various eye disorders and growing burden of geriatric population globally

The global ocular implants market was valued at USD 5,060.43 million in 2023, growing at a CAGR of 4.51% during the forecast period from 2024 to 2030 to reach USD 6,561.46 million by 2030. The ocular implants market is slated to witness growth owing to factors such as a rise in the cases of various eye disorders like glaucoma, cataract, presbyopia, and myopia among others, escalating burden of the geriatric population globally, and the increasing technological advancements to further enhance product safety and biocompatibility is expected to result in appreciable revenue growth in the ocular implants market during the forecast period (2024-2030).

Ocular Implants Market Dynamics:

One of the noteworthy drivers of the ocular implant market is the rise in the prevalence of eye disorders such as cataracts, glaucoma, presbyopia, and myopia. For instance, according to the World Health Organization (2023), the prevalence of population having near or distance vision impairment stands at a staggering figure of 2.2 billion globally, with which almost half of the affected people could have prevented vision impairment, or the cases have not yet been addressed. According to the same source, the prevalence rate of unaddressed cataracts and glaucoma in the year 2020 were 94 million and 7.7 million respectively. The number of refractive errors such as myopia and presbyopia is also said to increase in the upcoming years. For example, as per the International Myopia Institute (2023), 30% of the world is currently myopic and by 2050, the number of myopic people is said to grow to 50%, accounting for five billion. The aforementioned source further stated that myopia is more prevalent in East and South East Asia where countries such as South Korea, China, and Japan have a prevalence of 80% to 90%. In the case of presbyopia, as per the data cited by the World Health Organization in their World Report on Vision (2019), presbyopia accounted for approximately 1.8 billion cases across the globe in the year 2018.

Additionally, the rising geriatric population prone to the development of multiple eye disorders including cataracts, age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and presbyopia, among others is further going to accelerate the ocular implants market. According to the data provided by the WHO (2023), in 2020, about one billion people across the world were over the age of 60. The source mentioned above added by stating that by 2050, the elderly population aged 60 and above is expected to double in number representing about 2.1 billion people. Also, people in the age group of 80 and above are estimated to triple between 2020 and 2050 to reach 426 million.

However, the lack of coverage of premium lenses and complications associated with surgical procedures and devices may act as restraining factors for the ocular implant market.

The ocular implants market reported a short period of a setback in market growth due to the implementation of lockdown as necessary measures to break the chain of COVID-19 infection transmission. The COVID-19 pandemic resulted in the massive reorganization of healthcare services and the carrying out of medical procedures. Many countries segregated medical procedures based on the need for urgent medical care to streamline the workflow during the COVID-19 crisis and saw various medical procedures considered elective being suspended. For instance, in March 2020, the American Academy of Ophthalmology (AAO) recommended ophthalmologists to stop all routine activities and restrict their treatment only to urgent and emergent cases; the AAO also recommended that clinical activities could be performed with continued caution in compliance with local regulations. Furthermore, the procedures of intra-ocular surgeries decreased as it became difficult to procure ocular implants during the lockdown period. This led to a decrease in product demand from regular levels. However, the resumption of activities across industries including the healthcare sector has been uplifting the ocular implants market and will drive growth during the forecast period from 2024-2030.

Ocular Implants Market Segment Analysis:

Ocular Implants Market by Type (Intraocular Lenses, Corneal Implants, Glaucoma Implants, Artificial Iris, and Others), Material (Biodegradable and Non-biodegradable), Application (Cataract, Glaucoma Surgery, Oculoplasty, Drug Delivery, Macular Degeneration, and Others), End-user (Hospitals, Eye Speciality Clinics, Ambulatory Surgical Centres), Geography (North-America, Europe, Asia-Pacific, Rest of the World).

In the type segment of the ocular implants market, the intraocular lenses category held the highest revenue share of 78% in 2022.

This can be attributed to the various properties, technical advantages, and increasing product development activities such as collaborations and regulatory approvals of intraocular lenses during the given forecast period.

IOLs are an excellent alternative to the excimer laser procedure (LASIK), they also eliminate the need for glasses or contact lenses post-surgery for most patients and the cataract will not return, as the lens has been removed.

IOLs such as aspheric IOLs eliminate the positive spherical aberration and offer patients improved contrast sensitivity, enhanced functional vision, and superior night driving ability.

Multifocal IOLs restore visual function and allow spectacle independence after their implantation with great levels of patient satisfaction and require less or no additional care or routine replacement.

Also, the toric IOLs are a type of monofocal IOL that helps correct corneal astigmatism of 1 D or more in cases undergoing cataract surgery and achieve spectacle independence for distance vision. For example, Auroflex Toric developed by Aurolab offers the perceivable benefit of superior quality vision for a patient with corneal astigmatism.

Extended Depth of Focus (EDOF or EDF), or Extended Range of Vision, is a new technology that has recently emerged in the treatment of Presbyopia-correcting IOLs and works by creating a single elongated focal point to enhance "range of vision" or "depth of focus."

Thereby, considering the growing demand for this product type, numerous new products are being launched in the market. For example, In May 2022, Ophtec BV introduced the Precizon Presbyopic Toric IOL. In November 2020, HumanOptics launched the trifocal posterior chamber IOL for presbyopia correction, TRIVA in Europe. In September 2019, BVI®, through its PhysIOL subsidiary, launched FineVision Triumf- the first and only Trifocal EDOF IOL in the European market.

Therefore, considering the advantages associated with intraocular implants and their growing popularity, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global ocular implants market during the forecast period.

North America is expected to dominate the overall Ocular Implants Market:

Among all the regions, North America held the largest share of 45.18% in 2022. This can be ascribed to the growing prevalence of eye disorders and refractive errors such as cataracts, glaucoma, myopia, presbyopia, and others.

As per the National Diabetics Statistics Report by the Centers for Disease Control and Prevention (CDC, 2020), about 34.2 million Americans had diabetes in 2020. The report further stated that approximately 88 million Americans showed pre-diabetes levels. The CDC considers diabetes to be one of the major risk factors that may lead to glaucoma development.

In addition, according to the National Eye Institute, 2020, the United States recorded 7.7 million diabetic retinopathy cases and 24 million cataract cases in 2020, and it is expected to reach 11.3 million and 38 million, respectively, by 2030.

A cataract is the major cause of visual impairment, and geriatric ocular issues have been emerging as potential factors in the past few years in developing countries.

All the above-stated ophthalmic issues will require ocular implants at some point, for their correction, which is expected to increase the demand for ocular implants.

In addition to a large patient pool associated with refractive errors in the North American region, high consumer awareness, new market launches, and the presence of a highly potent market in terms of product development are also some key factors driving the growth of the North American ocular implants market. For instance, in July 2020, the United States Food and Drug Administration approved Allergan's drug-releasing implant, DURYSTA, for administration within the cavities of the eye to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Therefore, the above-mentioned factors are going to bolster the North America ocular implant markets.

Ocular Implants Market Key Players:

Some of the key market players operating in the Ocular Implants market include Alcon, Johnson & Johnson Services Inc., Bausch Health Companies Inc., ZEISS International, Glaukos Corporation, AbbVie Inc., MORCHER® GmbH, HumanOptics Holding AG, Alimera Sciences, Advanced Artificial Eyes, Erickson Laboratories, Midwest Eye Laboratories, Inc., EyeYon, EyePoint Pharmaceuticals, Inc., HOYA Corporation, SMR Ophthalmic Pvt. Ltd, Gulden Ophthalmics, AJL Ophthalmic S.A., KeraMed, Inc., Innovia Medical, and others.

Recent Developmental Activities in the Ocular Implants Market:

In April 2022, STAAR SURGICAL announced the launch of the EVO Vision Implantable Collamer Lens at the American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) in Washington D.C.

In November 2022, Alcon Inc. took over Invantis Inc., which specializes in glaucoma ocular devices that are micro-invasive, in California to expand its glaucoma surgical implants segment.

In May 2020, Bausch+Lomb, a part of Bosch Health Companies Inc., announced the European launch of LuxSmart and LuxGood Preloaded Intraocular lenses. Some of the features of these lenses are their monofocal periphery, acrylic hydrophobicity along with UV light protection.

Key Takeaways from the Ocular Implants Market Report Study

Market size analysis for current ocular implants market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the ocular implant market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years.

Key companies dominating the global ocular implants market.

Various opportunities available for the other competitor in the ocular implants market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current ocular implants market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for ocular implant market growth in the coming future?

Target Audience who can be benefited from this Ocular Implants Market Report Study

Ocular Implants providers

Research organizations and consulting companies

Ocular Implants -related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in ocular implants

Various end users who want to know more about the ocular implants market and the latest technological developments in the ocular implants market.

Frequently Asked Questions for the Ocular Implants Market:

1. What are ocular implants?

Ocular implants are small devices designed to be inserted into the eye, made of medical-grade plastic acrylic. Ocular implants form a part of surgical procedures that help in the fixation of cataracts and other vision impairments such as glaucoma, presbyopia, myopia, etc.

2. What is the market for global ocular implants?

The global ocular implants market was valued at USD 5,060.43 million in 2023, growing at a CAGR of 4.51% during the forecast period from 2024 to 2030 to reach USD 6,561.46 million by 2030.

3. What are the drivers for the global ocular implants market?

The ocular implants market is expected to grow significantly owing to factors such as a rise in the prevalence of eye disorders such as cataracts, glaucoma, presbyopia, myopia, and others coupled with a rising geriatric population globally. The rapidly growing technological advancements taking place in the ocular implants market with better technologies for delivering safe and biocompatible implants are further expected to result in appreciable revenue growth in the ocular implants market during the given forecast period (2024-2030).

4. Who are the key players operating in the global ocular implants market?

Some of the key market players operating in the ocular implants market include Alcon, Johnson & Johnson Services Inc., Bausch Health Companies Inc., ZEISS International, Glaukos Corporation, AbbVie Inc., MORCHER® GmbH, HumanOptics Holding AG, Alimera Sciences, Advanced Artificial Eyes, Erickson Laboratories, Midwest Eye Laboratories, Inc., EyeYon, EyePoint Pharmaceuticals, Inc., HOYA Corporation, SMR Ophthalmic Pvt. Ltd, Gulden Ophthalmics, AJL Ophthalmic S.A., KeraMed, Inc., Innovia Medical, and others.

5. Which region has the highest share in the ocular implants market?

North America is expected to dominate the overall ocular implants market during the forecast period, 2024 to 2030. This can be ascribed to the presence of a large number of cases having eye disorders such as glaucoma, cataract, presbyopia, and myopia along with the rising geriatric population in the region. In addition, it is a highly potent market in terms of technological developments and launches along with the presence of key market players among other factors in the region.

1. Ocular Implants Market Report Introduction

2. Ocular Implants Market Executive Summary

2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment

3. Regulatory Analysis

3.1. The United States
3.2. Europe
3.3. Japan
3.4. China

4. Ocular Implants Market Key Factors Analysis

4.1. Ocular Implants Market Drivers
- 4.1.1. Rise in the cases of eye disorders like cataracts, glaucoma, presbyopia, and myopia
- 4.1.2. The escalating burden of the geriatric population globally
- 4.1.3. Technological advancements in product design
4.2. Ocular Implants Market Restraints and Challenges
- 4.2.1. Complications associated with surgical procedures and devices
- 4.2.2. Lack of coverage of the premium lens
4.3. Ocular Implants Market Opportunities
- 4.3.1. Improving Product safety and biocompatibility
- 4.3.2. Rising development of advanced ocular implants

5. Ocular Implants Market Porter's Five Forces Analysis

5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Ocular Implants Market

7. Ocular Implants Market Layout

7.1. By Type:
- 7.1.1. Intraocular lenses
- 7.1.2. Corneal Implants
- 7.1.3. Glaucoma Implants
- 7.1.4. Artificial Iris
- 7.1.5. Others
7.2. By Material
- 7.2.1. Biodegradable
- 7.2.2. Non-biodegradable
7.3. By Application
- 7.3.1. Cataract
- 7.3.2. Glaucoma Surgery
- 7.3.3. Oculoplasty
- 7.3.4. Drug Delivery
- 7.3.5. Macular Degeneration
- 7.3.6. Others
7.4 By End User
- 7.4.1. Hospitals
- 7.4.2. Eye Speciality Clinics
- 7.4.3. Ambulatory Surgical Centres
7.5. By Geography
- 7.5.1. North America
  - 7.5.1.1. United States Ocular Implants Market in USD million (2021-2030)
  - 7.5.1.2. Canada Ocular Implants Market in USD million (2021-2030)
  - 7.5.1.3. Mexico Ocular Implants Market in USD million (2021-2030)
- 7.5.2. Europe
  - 7.5.2.1. France Ocular Implants Market in USD million (2021-2030)
  - 7.5.2.2. Germany Ocular Implants Market in USD million (2021-2030)
  - 7.5.2.3. United Kingdom Ocular Implants Market in USD million (2021-2030)
  - 7.5.2.4. Italy Ocular Implants Market in USD million (2021-2030)
  - 7.5.2.5. Spain Ocular Implants Market in USD million (2021-2030)
  - 7.5.2.6. Rest of Europe Ocular Implants Market in USD million (2021-2030)
- 7.5.3. Asia-Pacific
  - 7.5.3.1. China Ocular Implants Market in USD million (2021-2030)
  - 7.5.3.2. Japan Ocular Implants Market in USD million (2021-2030)
  - 7.5.3.3. India Ocular Implants Market in USD million (2021-2030)
  - 7.5.3.4. Australia Ocular Implants Market in USD million (2021-2030)
  - 7.5.3.5. South Korea Ocular Implants Market in USD million (2021-2030)
  - 7.5.3.6. Rest of Asia Pacific Ocular Implants Market in USD million (2021-2030)
- 7.5.4. Rest of the World (RoW)
  - 7.5.4.1. Middle East Ocular Implants Market in USD million (2021-2030)
  - 7.5.4.2. Africa Ocular Implants Market in USD million (2021-2030)
  - 7.5.4.3. South America Ocular Implants Market in USD million (2021-2030)

8. Ocular Implants Market Company and Product Profiles

8.1. Alcon
- 8.1.1. Company Overview
- 8.1.2. Company Snapshot
- 8.1.3. Financial Overview
- 8.1.4. Product Listing
- 8.1.5. Entropy
8.2. Johnson & Johnson Services Inc.
- 8.2.1. Company Overview
- 8.2.2. Company Snapshot
- 8.2.3. Financial Overview
- 8.2.4. Product Listing
- 8.2.5. Entropy
8.3. Bausch Health Companies Inc.
- 8.3.1. Company Overview
- 8.3.2. Company Snapshot
- 8.3.3. Financial Overview
- 8.3.4. Product Listing
- 8.3.5. Entropy
8.4. ZEISS International
- 8.4.1. Company Overview
- 8.4.2. Company Snapshot
- 8.4.3. Financial Overview
- 8.4.4. Product Listing
- 8.4.5. Entropy
8.5. Glaukos Corporation
- 8.5.1. Company Overview
- 8.5.2. Company Snapshot
- 8.5.3. Financial Overview
- 8.5.4. Product Listing
- 8.5.5. Entropy
8.6. AbbVie Inc.
- 8.6.1. Company Overview
- 8.6.2. Company Snapshot
- 8.6.3. Financial Overview
- 8.6.4. Product Listing
- 8.6.5. Entropy
8.7. MORCHER® GmbH
- 8.7.1. Company Overview
- 8.7.2. Company Snapshot
- 8.7.3. Financial Overview
- 8.7.4. Product Listing
- 8.7.5. Entropy
8.8. HumanOptics Holding AG
- 8.8.1. Company Overview
- 8.8.2. Company Snapshot
- 8.8.3. Financial Overview
- 8.8.4. Product Listing
- 8.8.5. Entropy
8.9. Alimera Sciences
- 8.9.1. Company Overview
- 8.9.2. Company Snapshot
- 8.9.3. Financial Overview
- 8.9.4. Product Listing
- 8.9.5. Entropy
8.10. Advanced Artificial Eyes
- 8.10.1. Company Overview
- 8.10.2. Company Snapshot
- 8.10.3. Financial Overview
- 8.10.4. Product Listing
- 8.10.5. Entropy
8.11. Erickson Laboratories
- 8.11.1. Company Overview
- 8.11.2. Company Snapshot
- 8.11.3. Financial Overview
- 8.11.4. Product Listing
- 8.11.5. Entropy
8.12. Midwest Eye Laboratories, Inc.
- 8.12.1. Company Overview
- 8.12.2. Company Snapshot
- 8.12.3. Financial Overview
- 8.12.4. Product Listing
- 8.12.5. Entropy
8.13. EyeYon
- 8.13.1. Company Overview
- 8.13.2. Company Snapshot
- 8.13.3. Financial Overview
- 8.13.4. Product Listing
- 8.13.5. Entropy
8.14. EyePoint Pharmaceuticals, Inc.
- 8.14.1. Company Overview
- 8.14.2. Company Snapshot
- 8.14.3. Financial Overview
- 8.14.4. Product Listing
- 8.14.5. Entropy
8.15. HOYA Corporation
- 8.15.1. Company Overview
- 8.15.2. Company Snapshot
- 8.15.3. Financial Overview
- 8.15.4. Product Listing
- 8.15.5. Entropy
8.16. SMR Ophthalmic Pvt. Ltd.
- 8.16.1. Company Overview
- 8.16.2. Company Snapshot
- 8.16.3. Financial Overview
- 8.16.4. Product Listing
- 8.16.5. Entropy
8.17. Gulden Ophthalmics
- 8.17.1. Company Overview
- 8.17.2. Company Snapshot
- 8.17.3. Financial Overview
- 8.17.4. Product Listing
- 8.17.5. Entropy
8.18. AJL Ophthalmic S.A.
- 8.18.1. Company Overview
- 8.18.2. Company Snapshot
- 8.18.3. Financial Overview
- 8.18.4. Product Listing
- 8.18.5. Entropy
8.19. KeraMed, Inc.
- 8.19.1. Company Overview
- 8.19.2. Company Snapshot
- 8.19.3. Financial Overview
- 8.19.4. Product Listing
- 8.19.5. Entropy
8.20. Innovia Medical
- 8.20.1. Company Overview
- 8.20.2. Company Snapshot
- 8.20.3. Financial Overview
- 8.20.4. Product Listing
- 8.20.5. Entropy